Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Special Report Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsAuthored by Nathan Reiff. Article Posted: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: Elon Musk already made me a "wealthy man"
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion over the next eight years. Companies often take a niche approach, developing medicines that target specific cancers with dedicated mechanisms. Fortunately, several promising treatments have shown impressive potential—and with that comes the possibility of significant sales. Two smaller biotech companies are experiencing notable share-price momentum thanks to their leading oncology medicines. Besides offering strong therapeutic potential, these drugs could help the firms move toward greater stability beyond penny-stock (or otherwise unstable) status and eventually toward long-term profitability. In both cases, significant challenges remain, making these typical biotech investments high-risk—yet potentially high-reward—for investors willing to take a chance. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle Silver Is Now a Growth AND Income Play For decades, silver paid nothing. That just changed. One tiny ETF is delivering 20% annualized distributions plus 68% share appreciation in just 5 months. Click here to learn more about this fund. Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% in a week when the S&P 500 dipped about 1%. That rally added to IOVA's year-to-date (YTD) gains, which have more than doubled the stock so far this year. Still, with a consensus price target of $8.88, Wall Street anticipates more upside—that target implies another roughly 71% in potential gains. The main catalyst for Iovance's move is its lead product, Amtagvi, a T-cell immunotherapy for certain types of melanoma. Amtagvi has been approved for melanoma in the United States since 2024 and is gaining traction in sales, with additional approvals likely in the E.U., U.K., and other markets. When administered with Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi could reach more than $1 billion in U.S. peak sales. Amtagvi's broader potential may extend beyond melanoma: the drug received Fast Track designation from the FDA for non-small cell lung cancer and is being evaluated for other tumor types. Part of Iovance's outperformance this year also stems from its Q4 2025 earnings report, released in late February, in which the company posted narrower-than-expected losses per share and $5 million in revenue. For the full year, revenue rose about 30% year over year. Iovance is still a relatively small biotech (about a $2 billion market cap), and despite this year's rally, analysts remain cautious—roughly half of the dozen ratings are Hold or Sell. Risks are high: beyond the usual uncertainties for smaller biotech firms, Amtagvi's personalized, costly, and complex manufacturing process could constrain profitability even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, but its year-to-date performance dwarfs Iovance's: IBRX shares are up nearly 300% in 2026 alone, and that may be just the beginning. Analysts' consensus price target is $13.60, roughly 70% above the stock's current level even after this major uptick. ImmunityBio's leading product and primary growth driver is Anktiva, a treatment for specific types of bladder cancer. In February, shares spiked after the E.U. regulator granted the drug conditional marketing authorization—the latest in a string of global approvals. Anktiva's commercial performance is driving the firm's revenue: it generated $113 million in sales last year, a roughly 700% year-over-year increase. Like Amtagvi, Anktiva is being explored for additional cancer indications, which could further expand its market potential. Despite the dramatic run-up, IBRX remains highly speculative and risky. The company posted a full-year net loss of $351 million for 2025 as R&D spending continued to rise. Still, Wall Street appears more bullish on ImmunityBio than on Iovance: six of seven analysts rate the stock a Buy or equivalent. Both companies illustrate the classic biotech trade-off: meaningful upside tied to innovative oncology drugs, coupled with execution, manufacturing, and clinical risks that can materially affect outcomes. Investors should weigh those risks carefully against the potential rewards.
| 
